In re MannKind Corporation Securities Litigation, No. 11-CV-00929 (GAF) (SSxx) (C.D. Cal.) This action alleged that the defendants falsely represented the prospects for its AFREZZA product for the treatment of adult patients with Type 1 and Type 2 diabetes for the control of hyperglycemia, while failing to disclose that the FDA had not approved the protocol that MannKind used for purposes of the FDA approval process. Pomerantz obtained a settlement valued at $22,000,000, which included a cash component of $16,000,000, with the remaining component comprised of MannKind securities.